Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiinflammatory therapy for dry eye.

Stephen C Pflugfelder1

  • 1Ocular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas 77030, USA. stevenp@bcm.tmc.edu

American Journal of Ophthalmology
|February 14, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibitory effect of the water-soluble retinoid X receptor partial agonist CAt-PMN on allergic conjunctivitis-like responses in mice.

Experimental eye research·2026
Same author

Modulation of corneal sensory processing and pain responses by dry eye and corneal wounding.

Frontiers in cellular neuroscience·2026
Same author

Corneal Innervation Research at a Crossroads: A Tool-Driven Roadmap for the Future.

Investigative ophthalmology & visual science·2026
Same author

Rexinoid NEt-3IB Promotes Resident Macrophage Gene Expression and Mitigates Desiccation-Induced Ocular Surface Disease.

Investigative ophthalmology & visual science·2026
Same author

Ocular Surface Ulceration Associated With an Epidermal Growth Factor Receptor Inhibitor.

Cornea·2026
Same author

Investigating conjunctival immune pathways in Sjögren and non-Sjögren disease associated dry eye.

The ocular surface·2026

Inflammation plays a key role in dry eye disease (keratoconjunctivitis sicca). Anti-inflammatory therapies, such as the FDA-approved cyclosporine A, effectively treat dry eye symptoms and signs with good safety.

Area of Science:

  • Ophthalmology
  • Immunology
  • Inflammation Research

Background:

  • Dry eye disease is characterized by ocular surface inflammation, involving increased inflammatory mediators and immune cell infiltration.
  • Decreased tear secretion and turnover contribute to the inflammatory cycle in dry eye pathogenesis.

Discussion:

  • Inflammation is integral to the development of keratoconjunctivitis sicca (KCS), the ocular surface disease associated with dry eye.
  • Anti-inflammatory agents, including corticosteroids, cyclosporine, and doxycycline, have demonstrated clinical efficacy in managing KCS.

Key Insights:

  • Cyclosporine A emulsion is the first FDA-approved therapy for dry eye, demonstrating significant improvements in tear production and ocular surface staining.
  • Clinical trials confirm cyclosporine A's superiority over vehicle in reducing dry eye symptoms and artificial tear dependency.

Related Experiment Videos

  • No significant ocular or systemic toxicity was observed with cyclosporine A treatment.

    • Outlook:

    • Targeting ocular surface and lacrimal gland inflammation is crucial for effective dry eye management.
    • Cyclosporine A represents a safe and effective long-term therapeutic option for patients with KCS.
    • Further research into anti-inflammatory mechanisms may yield novel treatments for dry eye disease.